Loading...
Header Logo
Keywords
Last Name
Institution

WILLIAM NASSIB WILLIAM JR

TitleAssociate Professor
InstitutionMD Anderson
DepartmentThoracic Head & Neck Medical Oncology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. William WN, Feng L, Ferrarotto R, Ginsberg L, Kies M, Lippman S, Glisson B, Kim ES. Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial. J Am Acad Dermatol. 2017 Dec; 77(6):1110-1113.e2. PMID: 28964539.
      View in: PubMed
    2. El Haddad D, Iliescu C, Yusuf SW, William WN, Khair TH, Song J, Mouhayar EN. Outcomes of Cancer Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion. J Am Coll Cardiol. 2015 Sep 08; 66(10):1119-28. PMID: 26337990.
      View in: PubMed
    3. Ozgur OK, Yin V, Chou E, Ball S, Kies M, William WN, Migden M, Thuro BA, Esmaeli B. Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome. Am J Ophthalmol. 2015 Aug; 160(2):220-227.e2. PMID: 25935097.
      View in: PubMed
    4. Zhang J, Gold KA, Lin HY, Swisher SG, Xing Y, Lee JJ, Kim ES, William WN. Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry. J Thorac Oncol. 2015 Apr; 10(4):682-90. PMID: 25590605.
      View in: PubMed
    5. William WN, El-Naggar AK. A novel target for oral cancer chemoprevention? Notch quite, yet…. Cancer Prev Res (Phila). 2015 Apr; 8(4):262-5. PMID: 25712052.
      View in: PubMed
    6. Gay CM, William WN, Wang SA, Oo TH. Thymoma complicated by acquired amegakaryocytic thrombocytopenia and pure red cell aplasia. J Natl Compr Canc Netw. 2014 Nov; 12(11):1505-9. PMID: 25361796.
      View in: PubMed
    7. Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, Seth S, Chow CW, Cao Y, Gumbs C, Gold KA, Kalhor N, Little L, Mahadeshwar H, Moran C, Protopopov A, Sun H, Tang J, Wu X, Ye Y, William WN, Lee JJ, Heymach JV, Hong WK, Swisher S, Wistuba II, Futreal PA. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014 Oct 10; 346(6206):256-9. PMID: 25301631.
      View in: PubMed
    8. Faiz SA, Balachandran D, Hessel AC, Lei X, Beadle BM, William WN, Bashoura L. Sleep-related breathing disorders in patients with tumors in the head and neck region. Oncologist. 2014 Nov; 19(11):1200-6. PMID: 25273079.
      View in: PubMed
    9. William WN, Swisher SG. Optimizing surrogate end points for preoperative systemic therapies in non-small cell lung cancers. Ann Surg Oncol. 2014 Sep; 21(9):2813-4. PMID: 24833104.
      View in: PubMed
    10. D'souza G, Carey TE, William WN, Nguyen ML, Ko EC, Riddell J, Pai SI, Gupta V, Walline HM, Lee JJ, Wolf GT, Shin DM, Grandis JR, Ferris RL. Epidemiology of head and neck squamous cell cancer among HIV-infected patients. J Acquir Immune Defic Syndr. 2014 Apr 15; 65(5):603-10. PMID: 24326607.
      View in: PubMed
    11. Foy JP, Bertolus C, William WN, Saintigny P. Oral premalignancy: the roles of early detection and chemoprevention. Otolaryngol Clin North Am. 2013 Aug; 46(4):579-97. PMID: 23910471.
      View in: PubMed
    12. Gold KA, Neskey M, William WN. The role of systemic treatment before, during, and after definitive treatment. Otolaryngol Clin North Am. 2013 Aug; 46(4):645-56. PMID: 23910475.
      View in: PubMed
    13. William WN, Papadimitrakopoulou VA. Optimizing biomarkers and endpoints in oral cancer chemoprevention trials. Cancer Prev Res (Phila). 2013 May; 6(5):375-8. PMID: 23639861.
      View in: PubMed
    14. Zhong LP, Zhu DW, William WN, Liu Y, Ma J, Yang CZ, Yang X, Wang LZ, Li J, Myers JN, Lee JJ, Zhang CP, Zhang ZY. Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease. Mol Cancer Ther. 2013 Jun; 12(6):1112-21. PMID: 23515614.
      View in: PubMed
    15. William WN, Pataer A, Kalhor N, Correa AM, Rice DC, Wistuba II, Heymach J, Lee JJ, Kim ES, Munden R, Gold KA, Papadimitrakopoulou V, Swisher SG, Erasmus JJ. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2013 Feb; 8(2):222-8. PMID: 23287849.
      View in: PubMed
    16. El-Sawy T, Sabichi AL, Myers JN, Kies MS, William WN, Glisson BS, Lippman S, Esmaeli B. Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma. Arch Ophthalmol. 2012 Dec; 130(12):1608-11. PMID: 23229707.
      View in: PubMed
    17. Zhong LP, Zhang CP, Ren GX, Guo W, William WN, Sun J, Zhu HG, Tu WY, Li J, Cai YL, Wang LZ, Fan XD, Wang ZH, Hu YJ, Ji T, Yang WJ, Ye WM, Li J, He Y, Wang YA, Xu LQ, Wang BS, Kies MS, Lee JJ, Myers JN, Zhang ZY. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol. 2013 Feb 20; 31(6):744-51. PMID: 23129742.
      View in: PubMed
    18. Beadle BM, William WN, McLemore MS, Sturgis EM, Williams MD. p16 expression in cutaneous squamous carcinomas with neck metastases: a potential pitfall in identifying unknown primaries of the head and neck. Head Neck. 2013 Nov; 35(11):1527-33. PMID: 23108906.
      View in: PubMed
    19. William WN. Oral premalignant lesions: any progress with systemic therapies? Curr Opin Oncol. 2012 May; 24(3):205-10. PMID: 22273549.
      View in: PubMed
    20. Buzaid AC, Schmerling RA, Vieira Guedes RA, de Freitas D, William WN. High-dose interleukin-2 in patients with metastatic melanoma whose disease progressed after biochemotherapy. Melanoma Res. 2011 Aug; 21(4):370-5. PMID: 21558968.
      View in: PubMed
    21. William WN, Glisson BS. Novel strategies for the treatment of small-cell lung carcinoma. Nat Rev Clin Oncol. 2011 Jun 21; 8(10):611-9. PMID: 21691321.
      View in: PubMed
    22. William WN, Kim JS, Liu DD, Solis L, Behrens C, Lee JJ, Lippman SM, Kim ES, Hong WK, Wistuba II, Lee HY. The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Ann Oncol. 2012 Jan; 23(1):78-85. PMID: 21430184.
      View in: PubMed
    23. Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JV. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther. 2010 Jun; 9(6):1755-63. PMID: 20530716.
      View in: PubMed
    24. William WN, Kies MS, Fossella FV, Liu DD, Gladish G, Tse WH, Lee JJ, Hong WK, Lippman SM, Kim ES. Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. Cancer. 2010 May 15; 116(10):2401-8. PMID: 20225327.
      View in: PubMed
    25. William WN, Uyeki J, Johnson FM, Feng L, Peeples BO, Fossella FV, Karp DD, Blumenschein GR, Stewart DJ, Glisson BS. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma. Cancer. 2010 May 15; 116(10):2409-15. PMID: 20225329.
      View in: PubMed
    26. William WN, Khuri FR, Fossella FV, Glisson BS, Zinner RG, Lee JJ, Herbst RS, Lippman SM, Kim ES. Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy. Am J Clin Oncol. 2010 Apr; 33(2):148-52. PMID: 19687727.
      View in: PubMed
    27. Kies MS, Holsinger FC, Lee JJ, William WN, Glisson BS, Lin HY, Lewin JS, Ginsberg LE, Gillaspy KA, Massarelli E, Byers L, Lippman SM, Hong WK, El-Naggar AK, Garden AS, Papadimitrakopoulou V. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol. 2010 Jan 01; 28(1):8-14. PMID: 19917840.
      View in: PubMed
    28. William WN, Gold KA, Kim ES. Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options. Ann Oncol. 2009 Sep; 20(9):1455-1457. PMID: 19704160.
      View in: PubMed
    29. Kim ES, Mauer AM, William WN, Tran HT, Liu D, Lee JJ, Windt P, Hong WK, Vokes EE, Herbst RS. A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer. 2009 Apr 15; 115(8):1713-22. PMID: 19208430.
      View in: PubMed
    30. William WN, Lin HY, Lee JJ, Lippman SM, Roth JA, Kim ES. Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. Chest. 2009 Sep; 136(3):701-709. PMID: 19318668.
      View in: PubMed
    31. William WN, Heymach JV, Kim ES, Lippman SM. Molecular targets for cancer chemoprevention. Nat Rev Drug Discov. 2009 Mar; 8(3):213-25. PMID: 19247304.
      View in: PubMed
    32. William WN, Lee JL, Shin DM, Hong WK, Liu S, Lee JJ, Lippman SM, Khuri FR, Kim ES. Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors. Am J Clin Oncol. 2009 Feb; 32(1):15-9. PMID: 19194117.
      View in: PubMed
    33. William WN, Kim ES, Herbst RS. Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck. Nat Clin Pract Oncol. 2009 Mar; 6(3):132-3. PMID: 19190590.
      View in: PubMed
    34. Papadimitrakopoulou V, Izzo JG, Liu DD, Myers J, Ceron TL, Lewin J, William WN, Atwell A, Lee JJ, Gillenwater A, El-Naggar A, Wu X, Lippman SM, Hittelman WN, Hong WK. Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila). 2009 Jan; 2(1):14-21. PMID: 19139013.
      View in: PubMed
    35. William WN, Lee JJ, Lippman SM, Martin JW, Chakravarti N, Tran HT, Sabichi AL, Kim ES, Feng L, Lotan R, Papadimitrakopoulou VA. High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila). 2009 Jan; 2(1):22-6. PMID: 19139014.
      View in: PubMed
    36. Papadimitrakopoulou VA, Lee JJ, William WN, Martin JW, Thomas M, Kim ES, Khuri FR, Shin DM, Feng L, Hong WK, Lippman SM. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol. 2009 Feb 01; 27(4):599-604. PMID: 19075276.
      View in: PubMed
    37. Papadimitrakopoulou VA, William WN, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, Peterson DE, Feng L, Atwell A, El-Naggar AK, Nathan CO, Helman JI, Du B, Yueh B, Boyle JO. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res. 2008 Apr 01; 14(7):2095-101. PMID: 18381950.
      View in: PubMed
    38. William WN, Zinner RG, Karp DD, Oh YW, Glisson BS, Phan SC, Stewart DJ. Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer. J Thorac Oncol. 2007 Aug; 2(8):745-50. PMID: 17762342.
      View in: PubMed
    39. Maluf FC, William WN, Rigato O, Menon AD, Parise O, Docema MF. Necrotizing fasciitis as a late complication of multimodal treatment for locally advanced head and neck cancer: a case report. Head Neck. 2007 Jul; 29(7):700-4. PMID: 17252595.
      View in: PubMed
    40. William WN, Ceddia RB, Curi R. Leptin controls the fate of fatty acids in isolated rat white adipocytes. J Endocrinol. 2002 Dec; 175(3):735-44. PMID: 12475384.
      View in: PubMed
    41. Ceddia RB, William WN, Curi R. The response of skeletal muscle to leptin. Front Biosci. 2001 Jan 01; 6:D90-7. PMID: 11145919.
      View in: PubMed
    42. Ceddia RB, William WN, Lima FB, Flandin P, Curi R, Giacobino JP. Leptin stimulates uncoupling protein-2 mRNA expression and Krebs cycle activity and inhibits lipid synthesis in isolated rat white adipocytes. Eur J Biochem. 2000 Oct; 267(19):5952-8. PMID: 10998055.
      View in: PubMed
    43. Ceddia RB, Lopes G, Souza HM, Borba-Murad GR, William WN, Bazotte RB, Curi R. Acute effects of leptin on glucose metabolism of in situ rat perfused livers and isolated hepatocytes. Int J Obes Relat Metab Disord. 1999 Nov; 23(11):1207-12. PMID: 10578212.
      View in: PubMed
    44. Ceddia RB, William WN, Carpinelli AR, Curi R. Modulation of insulin secretion by leptin. Gen Pharmacol. 1999 Feb; 32(2):233-7. PMID: 10188625.
      View in: PubMed
    45. Ceddia RB, William WN, Curi R. Comparing effects of leptin and insulin on glucose metabolism in skeletal muscle: evidence for an effect of leptin on glucose uptake and decarboxylation. Int J Obes Relat Metab Disord. 1999 Jan; 23(1):75-82. PMID: 10094581.
      View in: PubMed
    46. Ceddia RB, William WN, Curi R. Leptin increases glucose transport and utilization in skeletal muscle in vitro. Gen Pharmacol. 1998 Nov; 31(5):799-801. PMID: 9809481.
      View in: PubMed
    47. Ceddia RB, William WN, Lima FB, Curi R. Leptin inhibits insulin-stimulated incorporation of glucose into lipids and stimulates glucose decarboxylation in isolated rat adipocytes. J Endocrinol. 1998 Sep; 158(3):R7-9. PMID: 9846176.
      View in: PubMed
    48. Ceddia RB, William WN, Lima FB, Carpinelli AR, Curi R. Pivotal role of leptin in insulin effects. Braz J Med Biol Res. 1998 Jun; 31(6):715-22. PMID: 9698815.
      View in: PubMed
    49. Dexamethasone for Dyspnea in Cancer Patients. Journal of Pain and Symptom Management. 52:8-16.e1.
    50. Brain Metastasis from Solid Tumors. 3-29.
    51. Genomic heterogeneity of multiple synchronous lung cancer. Nature Communications. 7.
    52. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers. The Lancet Oncology. 15.
    53. Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus-associated oropharyngeal cancer. Cancer.
    54. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clinical Cancer Research. 22:609-620.
    55. New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development. Cancer Prevention Research. 8:1027-1035.
    56. Erratum. Journal of the American College of Cardiology. 66:2269.
    57. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy. The Lancet Oncology. 17:1672-1682.
    58. Reply to radiotherapy for human papillomavirus-positive oropharyngeal cancers in the National Cancer Data Base. Cancer. 122:3411-3412.
    59. Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma. Cancer.
    60. EGFR Tyrosine Kinase Inhibitors and Monoclonal Antibodies. 406-420.
    61. Induction chemotherapy for oral cavity cancer patients. Oral Oncology. 51:1069-1075.
    62. Erlotinib and the risk of oral cancer the erlotinib Prevention of Oral Cancer (EPOC) randomized clinical trial. JAMA oncology. 2:209-216.
    63. Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma. Thyroid. 27:81-87.
    64. Reirradiation of Head and Neck Cancers With Proton Therapy. International Journal of Radiation Oncology Biology Physics. 96:30-41.
    65. A novel target for oral cancer chemoprevention? Notch quite, yet.. Cancer Prevention Research. 8:262-265.
    66. Evolutionary action score of TP53 identifies high-risk mutations associated with decreased survival and increased distant metastases in head and neck cancer. Cancer Research. 75:1527-1536.
    67. STAT3-mediated IGF-2 secretion in the tumour microenvironment elicits innate resistance to anti-IGF-1R antibody. Nature Communications. 6.
    68. Outcomes for hypopharyngeal carcinoma treated with organ-preservation therapy. Head and Neck.
    69. Prognostic factors, predictive markers and cancer biology. Future Oncology. 12:2379-2386.
    70. Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck. Nature Reviews Clinical Oncology. 6:132-133.
    71. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells. Head and Neck.
    72. Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma. Oncotarget. 6:18707-18714.
    73. Reirradiation of head and neck cancers with intensity modulated radiation therapy. International Journal of Radiation Oncology Biology Physics. 95:1117-1131.
    74. Proposed staging system for patients with hpv-related oropharyngeal cancer based on nasopharyngeal cancer n categories. Journal of Clinical Oncology. 34:1848-1854.
    75. Recurrent oral cavity cancer. Head and Neck.
    76. Squamous-cell transformation in a patient with lung adenocarcinoma receiving erlotinib. Cancer Treatment Communications. 4:34-36.
    77. Barriers to a career focus in cancer prevention. Journal of Clinical Oncology. 34:186-193.
    78. In response. Cancer Prevention Research. 2:281-282.
    WILLIAM JR's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description